Urologiia (Moscow, Russia : 1999)
Is maximal androgenic blockade necessary in the treatment of prostatic cancer?
Abstract
As the literature data give arguments both pro and contra wide use of maximal androgenic block (MAB) in the treatment of prostatic cancer, the authors studied MAB in 200 patients. They came to the conclusion that MAB can be applied in patients with symptoms of disseminated prostatic cancer as neoadjuvant therapy before prostatectomy and as neoadjuvant and adjuvant therapy in planning radiotherapy.
Source and rights
Published by Urologiia (Moscow, Russia : 1999), 2003. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Published
- 2003
- Applies to
- 🇷🇺 Russia
- Scope
- National
- Journal
- Urologiia (Moscow, Russia : 1999)
- PubMed
- 14708235
- Added to Prognia
- 23 July 2026
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
